P49.01 Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC

Local consolidative therapy (LCT)has been confirmed to improve the overall survival of patients with non-small cell lung cancer (NSCLC) receiving targeted therapy and continuation of target therapy is currently recommended. it is unknown whether patients could benefit from targeted therapy holiday if no visible lesions and negative minimal residual disease (MRD) after LCT.